Fentanyl has emerged as the primary cause of illicit drug deaths in Canada and the United States, and its trafficking has ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx ...

Plus: A new non-opioid painkiller, the wave of lawsuits against Trump EOs, a key vote for RFK Jr., a big radiopharma deal and ...

SOUTH SAN FRANCISCO, Calif. - Vistagen Therapeutics (VTGN), a clinical-stage biopharmaceutical company with a market ...

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

Federal lawmakers are trying once again to push for a study on the “overmedication” of veterans by Department of Veterans ...

As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in ...

Robert F. Kennedy Jr.’s HHS nomination moves to a full Senate vote; Donald Trump’s tariff war sparks China-related concerns for biopharma; Pfizer, Merck and more announce Q4 and 2024 earnings; and the ...

FDA approves suzetrigine, a non-opioid painkiller that blocks sodium channels, offering potent relief without addiction risks.

While New Orleans prepares for the excitement of the big game, it’s important to remember that sports injuries aren’t limited to the professionals. High school athletes, weekend warriors, and generall ...

Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...